Genesys Pharma To Start Ph I With GPI-2A
Genesys Pharma has received approval from Canada's Health ProtectionBranch to begin a Phase I clinical trial with GPI-2A, its antisense drug for the treatment of HIV.
GPI-2A is a 20-mer oligonucleotide whose sequence is complementary to part of the p24 region of the HIV-mRNA. Once GPI-2A binds to the target, it inhibits production of the p24 protein, thus preventing the virus from replicating.
In preclinical studies, GPI-2A has been shown to be specific and potent inhibitor of HIV. It is able to accumulate in brain cells "at good concentrations," says the company, which may give it some advantages over other therapies which are unable to attack this HIV reservoir. Furthermore, its specificity to the p24 mRNA significantly minimizes the risk of side effects; in animals treated with 100 times the human dose, no side effects were observed. The company adds that the development of resistance to this drug "seems unlikely."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze